Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


03.04.2017

1 Acta Radiol
1 BJU Int
1 BMC Urol
1 Cancer Lett
2 Cancer Res
3 Eur Urol
1 Int J Oncol
1 Int J Urol
6 J Clin Oncol
1 J Urol
1 N Engl J Med
3 Nat Rev Urol
1 Oncogene
2 Oncol Rep
3 PLoS One
1 Prostate
1 Radiology
1 Urol Int
5 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Radiol

  1. WOO S, Kim SY, Cho JY, Kim SH, et al
    Length of capsular contact on prostate MRI as a predictor of extracapsular extension: which is the most optimal sequence?
    Acta Radiol. 2017;58:489-497.
    PubMed     Text format     Abstract available


    BJU Int

  2. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Text format     Abstract available


    BMC Urol

  3. UEMURA H, Matsubara N, Kimura G, Yamaguchi A, et al
    Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
    BMC Urol. 2017;17:20.
    PubMed     Text format    


    Cancer Lett

  4. O'MALLEY J, Kumar R, Kuzmin A, Pliss A, et al
    Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.
    Cancer Lett. 2017 Mar 23. pii: S0304-3835(17)30199.
    PubMed     Text format     Abstract available


    Cancer Res

  5. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
    A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
    Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
    PubMed     Text format     Abstract available

  6. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
    Mutational Landscape of Aggressive Prostate Tumors in African American Men.
    Cancer Res. 2016;76:1860-8.
    PubMed     Text format     Abstract available


    Eur Urol

  7. MOLDOVAN PC, Van den Broeck T, Sylvester R, Marconi L, et al
    What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30115.
    PubMed     Text format     Abstract available

  8. LAMB BW, Violet J, Siva S, Murphy DG, et al
    Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Eur Urol. 2017 Mar 20. pii: S0302-2838(17)30179.
    PubMed     Text format    

  9. PORTER LH, Lawrence MG, Ilic D, Clouston D, et al
    Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    Eur Urol. 2017 Mar 22. pii: S0302-2838(17)30178.
    PubMed     Text format     Abstract available


    Int J Oncol

  10. QIAN B, Yao Y, Liu C, Zhang J, et al
    SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
    Int J Oncol. 2017 Mar 22. doi: 10.3892/ijo.2017.3926.
    PubMed     Text format     Abstract available


    Int J Urol

  11. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Text format     Abstract available


    J Clin Oncol

  12. CHIN J, Rumble RB, Kollmeier M, Heath E, et al
    Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    J Clin Oncol. 2017 Mar 27:JCO2016720466. doi: 10.1200/JCO.2016.72.0466.
    PubMed     Text format     Abstract available

  13. YU JB
    Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales.
    J Clin Oncol. 2017 Mar 29:JCO2017727016. doi: 10.1200/JCO.2017.72.7016.
    PubMed     Text format    

  14. ARCANGELI G, Saracino B, Arcangeli S, Gomellini S, et al
    Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 29:JCO2016704189. doi: 10.1200/JCO.2016.70.4189.
    PubMed     Text format     Abstract available

  15. DALELA D, Santiago-Jimenez M, Yousefi K, Karnes RJ, et al
    Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
    J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918.
    PubMed     Text format     Abstract available

  16. GARZOTTO M
    Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
    J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684.
    PubMed     Text format    

  17. LEAPMAN MS, Cowan JE, Nguyen HG, Shinohara KK, et al
    Active Surveillance in Younger Men With Prostate Cancer.
    J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058.
    PubMed     Text format     Abstract available


    J Urol

  18. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  19. PINSKY PF, Prorok PC, Kramer BS
    Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    N Engl J Med. 2017;376:1285-1289.
    PubMed     Text format    


    Nat Rev Urol

  20. SIDAWAY P
    Prostate cancer: Testosterone replacement affects disease risk.
    Nat Rev Urol. 2017 Mar 29. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  21. SIDAWAY P
    Prostate cancer: Cabozantinib activates innate immunity.
    Nat Rev Urol. 2017 Mar 29. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  22. SIDAWAY P
    Prostate cancer: Clustirsin fails to improve outcomes.
    Nat Rev Urol. 2017 Mar 29. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncogene

  23. RUAN D, He J, Li CF, Lee HJ, et al
    Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  24. ZHAO Y, Yan M, Yun Y, Zhang J, et al
    MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5502.
    PubMed     Text format     Abstract available

  25. BAI Y, Xiao Y, Dai Y, Chen X, et al
    Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclindependent kinase 2 in human prostate carcinoma.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5501.
    PubMed     Text format     Abstract available


    PLoS One

  26. LE B, Powers GL, Tam YT, Schumacher N, et al
    Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    PLoS One. 2017;12:e0174658.
    PubMed     Text format     Abstract available

  27. SEO Y, Ryu K, Park J, Jeon DK, et al
    Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells.
    PLoS One. 2017;12:e0174935.
    PubMed     Text format     Abstract available

  28. LYNCH SM, Mitra N, Ross M, Newcomb C, et al
    A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.
    PLoS One. 2017;12:e0174548.
    PubMed     Text format     Abstract available


    Prostate

  29. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
    Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
    Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
    PubMed     Text format     Abstract available


    Radiology

  30. BARTH BK, De Visschere PJ, Cornelius A, Nicolau C, et al
    Detection of Clinically Significant Prostate Cancer: Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging-A Multireader Study.
    Radiology. 2017 Mar 27:162020. doi: 10.1148/radiol.2017162020.
    PubMed     Text format     Abstract available


    Urol Int

  31. SARKAR D, Ekwueme K, Parr N
    Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic Catheterisation.
    Urol Int. 2016;96:479-83.
    PubMed     Text format     Abstract available


    Urology

  32. PAKZAD R, Safiri S
    Unexplained Bone Pain is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: a Prospective Study; Methodological Issues.
    Urology. 2017 Mar 21. pii: S0090-4295(17)30272.
    PubMed     Text format    

  33. ZACHO HD, Morch CD, Barsi T, Mortensen JC, et al
    Reply to Letter-to-the-Editor: Unexplained Bone Pain is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: a Prospective Study, Published in Urology. 2017 Jan;99:148-154.
    Urology. 2017 Mar 20. pii: S0090-4295(17)30269.
    PubMed     Text format    

  34. JOSHI A, Nicholson C, Rhee H, Gustafson S, et al
    Incidental Malignancies identified during staging for Prostate Cancer with 68Ga -PSMA HBED-CC PET imaging.
    Urology. 2017 Mar 20. pii: S0090-4295(17)30271.
    PubMed     Text format     Abstract available

  35. JOHNSTON J, Struss WJ, Black PC
    Padeliporfin Vascular-Targeted Photodynamic Therapy Versus Active Surveillance in Men with Low-Risk Prostate Cancer (Clin1001 PCM301): an Open-Label, Phase 3, Randomised Control Trial.
    Urology. 2017 Mar 22. pii: S0090-4295(17)30274.
    PubMed     Text format    

  36. STRUSS WJ, Black PC
    Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Urology. 2017 Mar 22. pii: S0090-4295(17)30275.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: